Vertex Pharmaceuticals: 10 weeks into a sell signal, but the decline stalls
Vertex Pharmaceuticals is in week 10 of a sell signal, but the last 4 weeks tell a story that contradicts the decline: buying volume, CMF turned positive, and MACD histogram converging toward zero.
Vertiv Holdings: sell signal at week 1, but +150% above the long-term average puts the brakes on
Vertiv Holdings receives a weekly sell signal in its first week. The bearish structure is confirmed, yet the stock trades 150% above its 200-week average: the quality band flags trading as not recommended, and the model advises caution before any short entry.
Valero Energy Corporation: coverage complete, the runner hits choppier waters
At week 21, Valero Energy has completed the model's coverage with a 38% gain. The 40% runner is still alive, but the technical picture signals cooling momentum: MACD histogram in negative territory, CMF near zero, mixed weekly pattern.
Vanguard Dividend Appreciation ETF: 3 targets hit, the roadmap continues
At week 8, all 3 statistical model targets have already been hit, but the management roadmap runs to week 10. Stop at breakeven: zero risk. Strength at 20, fading signal, ranked 160th out of 161.
VGT at week 7: 2 targets hit, breakeven stop, and next management window ahead
Vanguard Information Technology ETF is at week 7 of a buy signal with 2 of the 3 model targets already hit and the stop moved to breakeven. The trade is up 14%, but conviction has eased: discipline points to management, not adding exposure.
Vanguard FTSE Europe ETF: 2 windows closed, but the signal is fading
VGK is at week 8 of a buy signal: 2 of the 3 model windows have already been reached, but the signal is fading — strength at 42 out of 100, IQS ordinary, MACD in bearish cross. Discipline points to week 10.